ITMCTR2000003323已完成4 期
A Multicenter, Randomized, Double Blind, Controlled Trial for Zhixue Quyu Mingmu Tablets and Compound Xue-shuan-tong Capsule in the Treatment of Retinal Vein Occlusion Patients with Blood Stasis and Yin Deficiency Syndrome
Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •(1) The patients who met the western medicine diagnosis standard of retinal vein occlusion and had definite bleeding;
- •(2) Those who meet the syndrome differentiation criteria of blood stasis and collateral injury, yin deficiency and internal heat;
- •(3) Patients within 3 months (excluding 3 months);
- •(4) 35-75 years old;
- •(5) Signing informed consent.
排除标准
- •(1) Patients with retinal vein occlusion and blood deficiency;
- •(2) The area of capillaries without perfusion of retinal vein occlusion was more than 5 disc diameters (PD) with neovascularization of disc, retina and iris, or the patients were treated by intraocular injection and laser therapy in the early stage;
- •(3) Patients with diabetic retinopathy, retinal detachment, proliferative retinopathy, senile maculopathy, glaucoma, severe cataract, inflammatory retinopathy and other eye diseases that affect the efficacy judgment;
- •(4) Eyeground hemorrhage caused by leukemia, trauma and other reasons;
- •(5) Pregnant, preparing pregnant or lactating women;
- •(6) Allergic constitution, especially allergic to fluorescein sodium injection;
- •(7) Patients with hypertension but still high blood pressure (systolic blood pressure >=160 or diastolic blood pressure >=100mmhg), severe cardiopulmonary insufficiency and severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, type II and III atrioventricular block, etc.) after drug treatment;
- •(8) In the patients with severe liver and kidney dysfunction, ALT and AST were more than 1.5 times of the upper limit of normal, Cr was more than 1.2 times of the upper limit of normal;
- •(9) Patients with severe primary diseases such as digestive system and hematopoietic system;
- •(10) Disabled patients (blind, deaf, dumb, mental disorders, mental disorders, etc.) as prescribed by law;
- •(11) Those who participated in other clinical trials in the past 3 months.
研究者
相似试验
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-ESMerck KGaA350
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-DEMerck KGaA160
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCnresectable Stage III Non-small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003265-34-HUMerck KGaA160
已完成
2 期
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancerlung cancerNon-small cell lung cancerNL-OMON52935Merck20
进行中（未招募）
1 期
M7824 with cCRT in Unresectable Stage III NSCLCEUCTR2018-003265-34-BEMerck KGaA160